$DHR · DANAHER CORP /DE/

Danaher reported Q3 FY2026 revenue of $6.554B (+8.3% YoY), GAAP EPS of $1.75, and net income of $1.235B. Gross margin was 58.5%, operating margin 19.0%. Acquisitions contributed 3.0% to sales growth; foreign currency added 1.5%; tariff refunds reduced sales by 0.5%. Core sales were flat in developed markets (mid-single digit growth in Western Europe offset by low-single digit decline in North America) and up 10% in high-growth markets, led by high-single digit growth in China. The Masimo acquisition drove $84M in nonrecurring inventory fair value step-up charges in Q3 and $130M year-to-date, plus $28M in pre-acquisition share-based payment settlements. Discrete tax benefits of $263M ($0.37 per diluted share) from audit settlements boosted Q3 results. Long-term debt rose to $24.4B from $18.4B at year-end 2025.

Extended-hours last trade $215.09, down -3.98% vs regular close, reflecting investor concern over Masimo integration costs and margin pressure despite top-line beat. Regular-session move since filing was -0.07%.

$157B life-sciences leader posted solid top-line growth but extended-hours selloff flags investor concern over Masimo integration costs and rising leverage.

Danaher's 10% core sales growth in high-growth markets and healthy China performance (high-single digits) contrast with peers facing biotech funding headwinds. The $1.4B StatLab bolt-on and Masimo integration signal continued M&A appetite in life sciences and diagnostics despite elevated debt levels.

Long-term debt jumped $6.0B to $24.4B in nine months, driven by the Masimo acquisition and StatLab close. Masimo inventory step-up charges ($130M YTD) and North America respiratory sales weakness in Diagnostics pressure near-term margins.